Phenylacetylgycine as Specific Biomarker for Phospholipidosis
Recently phenylacetylglycine (PAG) has been proposed as specific biomarker for phospholipidosis (J.K. Nicholson et al., A metabonomic approach to the investigation of drug-induced phospolipidosis, Biomarkers, 5(6), 2000: 410-423). Phenylacetylglycine is an endogenous metabolite excreted into urine by most species (as adduct of phenylacetate and glycine in the phenylalanine metabolism). In the case of phospholipidosis the concentration levels of PAG in urine are significantly increased.